Psoriatic Arthritis - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 231
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P8BDC2BEC63EN
Leaflet:

Download PDF Leaflet

Psoriatic Arthritis - Pipeline Review, H2 2016
Psoriatic Arthritis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis – Pipeline Review, H2 2016, provides an overview of the Psoriatic Arthritis (Musculoskeletal Disorders) pipeline landscape.

Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain and lower back pain. Risk factors include age, family history and psoriasis. Treatment includes NSAIDs, immunosuppressants and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriatic Arthritis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 9, 8, 10, 2, 15, 7 and 2 respectively.Psoriatic Arthritis.

Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Psoriatic Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Psoriatic Arthritis Overview
Therapeutics Development
Pipeline Products for Psoriatic Arthritis - Overview
Pipeline Products for Psoriatic Arthritis - Comparative Analysis
Psoriatic Arthritis - Therapeutics under Development by Companies
Psoriatic Arthritis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Psoriatic Arthritis - Products under Development by Companies
Psoriatic Arthritis - Companies Involved in Therapeutics Development

3SBIO INC.

AbbVie Inc
AbGenomics International, Inc.
Alteogen Inc.
Amgen Inc.
Biocon Limited
Bionovis SA
Bristol-Myers Squibb Company
Celgene Corporation
Coherus BioSciences, Inc.
Eli Lilly and Company
Forward Pharma A/S
Genor BioPharma Co Ltd
Innovent Biologics, Inc.
Johnson & Johnson
Kadmon Corporation, LLC
KPI Therapeutics, Inc.
Momenta Pharmaceuticals, Inc.
Morphotek, Inc.
Mycenax Biotech Inc.
NeuClone Pty Ltd
Novo Nordisk A/S
Oncobiologics, Inc.
Pfizer Inc.
Prothena Corporation Plc
Reliance Life Sciences Pvt. Ltd.
Sandoz International GmbH
Therapeutic Proteins International, LLC

UCB SA

Valeant Pharmaceuticals International, Inc.
Vitae Pharmaceuticals, Inc.
Vitaeris Inc
Xbrane Biopharma AB
Psoriatic Arthritis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abatacept - Drug Profile
AbGn-168H - Drug Profile
ABT-122 - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
adalimumab biosimilar - Drug Profile
apremilast - Drug Profile
apremilast - Drug Profile
bimekizumab - Drug Profile
certolizumab pegol biosimilar - Drug Profile
clazakizumab - Drug Profile
dalazatide - Drug Profile
dimethyl fumarate - Drug Profile
DNX-114 - Drug Profile
DNX-514 - Drug Profile
Drug to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile
etanercept - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
etanercept biosimilar - Drug Profile
golimumab - Drug Profile
golimumab biosimilar - Drug Profile
golimumab biosimilar - Drug Profile
guselkumab - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
infliximab biosimilar - Drug Profile
INV-17 - Drug Profile
itolizumab - Drug Profile
ixekizumab - Drug Profile
KANAb-071 - Drug Profile
KD-025 - Drug Profile
liraglutide - Drug Profile
PRX-003 - Drug Profile
risankizumab - Drug Profile
tofacitinib citrate - Drug Profile
upadacitinib tartrate - Drug Profile
ustekinumab biosimilar - Drug Profile
ustekinumab biosimilar - Drug Profile
VALBRO-03 - Drug Profile
VTP-43742 - Drug Profile
Psoriatic Arthritis - Dormant Projects
Psoriatic Arthritis - Discontinued Products
Psoriatic Arthritis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 226

LIST OF TABLES

Number of Products under Development for Psoriatic Arthritis, H2 2016
Number of Products under Development for Psoriatic Arthritis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Psoriatic Arthritis - Pipeline by 3SBio Inc., H2 2016
Psoriatic Arthritis - Pipeline by AbbVie Inc, H2 2016
Psoriatic Arthritis - Pipeline by AbGenomics International, Inc., H2 2016
Psoriatic Arthritis - Pipeline by Alteogen Inc., H2 2016
Psoriatic Arthritis - Pipeline by Amgen Inc., H2 2016
Psoriatic Arthritis - Pipeline by Biocon Limited, H2 2016
Psoriatic Arthritis - Pipeline by Bionovis SA, H2 2016
Psoriatic Arthritis - Pipeline by Bristol-Myers Squibb Company, H2 2016
Psoriatic Arthritis - Pipeline by Celgene Corporation, H2 2016
Psoriatic Arthritis - Pipeline by Coherus BioSciences, Inc., H2 2016
Psoriatic Arthritis - Pipeline by Eli Lilly and Company, H2 2016
Psoriatic Arthritis - Pipeline by Forward Pharma A/S, H2 2016
Psoriatic Arthritis - Pipeline by Genor BioPharma Co Ltd, H2 2016
Psoriatic Arthritis - Pipeline by Innovent Biologics, Inc., H2 2016
Psoriatic Arthritis - Pipeline by Johnson & Johnson, H2 2016
Psoriatic Arthritis - Pipeline by Kadmon Corporation, LLC, H2 2016
Psoriatic Arthritis - Pipeline by KPI Therapeutics, Inc., H2 2016
Psoriatic Arthritis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016
Psoriatic Arthritis - Pipeline by Morphotek, Inc., H2 2016
Psoriatic Arthritis - Pipeline by Mycenax Biotech Inc., H2 2016
Psoriatic Arthritis - Pipeline by NeuClone Pty Ltd, H2 2016
Psoriatic Arthritis - Pipeline by Novo Nordisk A/S, H2 2016
Psoriatic Arthritis - Pipeline by Oncobiologics, Inc., H2 2016
Psoriatic Arthritis - Pipeline by Pfizer Inc., H2 2016
Psoriatic Arthritis - Pipeline by Prothena Corporation Plc, H2 2016
Psoriatic Arthritis - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2016
Psoriatic Arthritis - Pipeline by Sandoz International GmbH, H2 2016
Psoriatic Arthritis - Pipeline by Therapeutic Proteins International, LLC, H2 2016
Psoriatic Arthritis - Pipeline by UCB SA, H2 2016
Psoriatic Arthritis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
Psoriatic Arthritis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2016
Psoriatic Arthritis - Pipeline by Vitaeris Inc, H2 2016
Psoriatic Arthritis - Pipeline by Xbrane Biopharma AB, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Psoriatic Arthritis - Dormant Projects, H2 2016
Psoriatic Arthritis - Dormant Projects (Contd..1), H2 2016
Psoriatic Arthritis - Discontinued Products, H2 2016 212

LIST OF FIGURES

Number of Products under Development for Psoriatic Arthritis, H2 2016
Number of Products under Development for Psoriatic Arthritis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Rheumatoid Arthritis - Pipeline Review, H2 2015 US$ 2,125.00 Dec, 2015 · 1175 pages

Ask Your Question

Psoriatic Arthritis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: